Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT …
Background Dual antiplatelet therapy (DAPT) with aspirin plus a P2Y 12 inhibitor prevents
ischaemic events after coronary stenting, but increases bleeding. Guidelines support …
ischaemic events after coronary stenting, but increases bleeding. Guidelines support …
Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial
Background It is unclear whether radial compared with femoral access improves outcomes
in unselected patients with acute coronary syndromes undergoing invasive management …
in unselected patients with acute coronary syndromes undergoing invasive management …
[HTML][HTML] Dual antiplatelet therapy after PCI in patients at high bleeding risk
Background The appropriate duration of dual antiplatelet therapy in patients at high risk for
bleeding after the implantation of a drug-eluting coronary stent remains unclear. Methods …
bleeding after the implantation of a drug-eluting coronary stent remains unclear. Methods …
Safety and efficacy of resolute zotarolimus-eluting stents compared with everolimus-eluting stents: a meta-analysis
R Piccolo, GG Stefanini, A Franzone… - Circulation …, 2015 - Am Heart Assoc
Background—Although new-generation drug-eluting stents represent the standard of care
among patients undergoing percutaneous coronary intervention, there remains debate …
among patients undergoing percutaneous coronary intervention, there remains debate …
Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin …
Background We hypothesised that ticagrelor, in combination with aspirin for 1 month,
followed by ticagrelor alone, improves outcomes after percutaneous coronary intervention …
followed by ticagrelor alone, improves outcomes after percutaneous coronary intervention …
Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized …
Importance Coronary plaques that are prone to rupture and cause adverse cardiac events
are characterized by large plaque burden, large lipid content, and thin fibrous caps. Statins …
are characterized by large plaque burden, large lipid content, and thin fibrous caps. Statins …
[HTML][HTML] Bivalirudin or unfractionated heparin in acute coronary syndromes
Background Conflicting evidence exists on the efficacy and safety of bivalirudin
administered as part of percutaneous coronary intervention (PCI) in patients with an acute …
administered as part of percutaneous coronary intervention (PCI) in patients with an acute …
Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease …
GG Stefanini, B Kalesan, PW Serruys, D Heg… - The Lancet, 2011 - thelancet.com
Background The effectiveness of durable polymer drug-eluting stents comes at the expense
of delayed arterial healing and subsequent late adverse events such as stent thrombosis …
of delayed arterial healing and subsequent late adverse events such as stent thrombosis …
Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the …
L Raeber, H Kelbaek, M Ostojic, A Baumbach, D Heg… - Jama, 2012 - jamanetwork.com
Context The efficacy and safety of drug-eluting stents compared with bare-metal stents
remains controversial in patients with ST-segment elevation myocardial infarction (STEMI) …
remains controversial in patients with ST-segment elevation myocardial infarction (STEMI) …
P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials
M Valgimigli, F Gragnano, M Branca, A Franzone… - Bmj, 2021 - bmj.com
Objective To assess the risks and benefits of P2Y 12 inhibitor monotherapy compared with
dual antiplatelet therapy (DAPT) and whether these associations are modified by patients' …
dual antiplatelet therapy (DAPT) and whether these associations are modified by patients' …